Usefulness of Plasma Amyloid as a Prescreener for the Earliest Alzheimer Pathological Changes Depends on the Study Population.

19 November 2019. doid: 10.1002/ana.25634

Prins S, Zhuparris A, Groeneveld GJ

View publication

https://pubmed.ncbi.nlm.nih.gov/31675127/

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

contact